Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart

Chen Yan, Clint L. Miller, Jun-ichi Abe

Abstract—Growing evidence suggests that multiple spatially, temporally, and functionally distinct pools of cyclic nucleotides exist and regulate cardiac performance, from acute myocardial contractility to chronic gene expression and cardiac structural remodeling. Cyclic nucleotide phosphodiesterases (PDEs), by hydrolyzing cAMP and cyclic GMP, regulate the amplitude, duration, and compartmentation of cyclic nucleotide–mediated signaling. In particular, PDE3 enzymes play a major role in regulating cAMP metabolism in the cardiovascular system. PDE3 inhibitors, by raising cAMP content, have acute inotropic and vasodilatory effects in treating congestive heart failure but have increased mortality in long-term therapy. PDE3A expression is downregulated in human and animal failing hearts. In vitro, inhibition of PDE3A function is associated with myocyte apoptosis through sustained induction of a transcriptional repressor ICER (inducible cAMP early repressor) and thereby inhibition of antiapoptotic molecule Bcl-2 expression. Sustained induction of ICER may also cause the change of other protein expression implicated in human and animal failing hearts. These data suggest that the downregulation of PDE3A observed in failing hearts may play a causative role in the progression of heart failure, in part, by inducing ICER and promoting cardiac myocyte dysfunction. Hence, strategies that maintain PDE3A function may represent an attractive approach to circumvent myocyte apoptosis and cardiac dysfunction. (Circ Res. 2007;100:489-501.)

Key Words: cAMP ■ PDE ■ ICER ■ heart failure ■ apoptosis

Cyclic AMP and cyclic cGMP are 2 critical intracellular second messengers that regulate a myriad of processes in the cardiovascular system, from short-term action in contraction/relaxation to long-term effects in cell growth/survival. For example, cAMP elevation, particularly through β-adrenergic receptor (β-AR) stimulation, has crucial positive inotropic and lusitropic effects when the cardiac demand is increased. However, cGMP, in most cases, exerts negative inotropic effects on the heart. Changes in intracellular cAMP and cGMP levels are often transient, and PDEs play very important roles in regulating the amplitude, duration, and compartmentation of cyclic nucleotide signaling. As a superfamily of enzymes, PDEs are subdivided into 11 broad families (PDE1 to PDE11) based on their tissue distribution, biochemical properties, and sensitivity to chemical inhibitors. With at least 21 genes encoding more than 50 PDE isoforms,
cAMP-Hydrolyzing PDEs in the Heart

<table>
<thead>
<tr>
<th>PDE Family</th>
<th>Isoform*</th>
<th>Potential Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDE1</td>
<td>PDE1A</td>
<td>Unknown</td>
</tr>
<tr>
<td>cAMP, cGMP</td>
<td>PDE1C</td>
<td></td>
</tr>
</tbody>
</table>

- **PDE2**
  - cAMP, cGMP
  - PDE2A
  - cGMP counteracting cAMP signaling and inotropy

- **PDE3**
  - cAMP, cGMP
  - PDE3A
  - PDE3 regulates myocyte contraction and relaxation via L-type Ca2+ channels and SERCA2, respectively
  - PDE3B
  - PED3A regulates ICER expression and myocyte apoptosis, and Cardiac PDE3B constitutively associates with PI3K (phospho-inositide 3-kinase γ), and mediates PI3Kγ control of L-type calcium current

- **PDE4**
  - cAMP
  - PDE4A–D
  - PDE4D3 associates and regulates RyR2 phosphorylation

- **PDE5**
  - cGMP
  - PDE4D isofrom (such as PDE4D3 or -D5) is integral component of the β2-AR signaling complex and regulates β2-AR PKA phosphorylation and G protein switching from G(s) to G(i)
  - PDE4D3 regulates local cAMP signaling by associating with a macrocomplex containing mAKAP, PKA, big MAP Kinase, (BMK1/ERK5), the small GTPase Rap1, and the exchange factor Epac

*May vary between species, myocyte types, and cellular conditions.

Multiple Structurally and Functionally Distinct PDEs in the Heart

At least 5 different PDE families, PDE1, PDE2, PDE3, PDE4, and PDE5, have been described in the heart. Among them, PDE1 to PDE4 are all able to hydrolyze cAMP in vitro, whereas PDE5 exclusively hydrolyzes cGMP. The relative contribution of each PDE family likely varies among species, developmental stages, myocyte types (atrial versus ventricular), and the cellular conditions (such as basal versus stimulated, normal versus diseased). It has not been determined whether these isoforms are attributable to cardiac myocytes specifically or to other cardiac cell types, because most of these studies used whole hearts. Individual PDEs may regulate distinct cellular functions by selectively coupling to different cAMP pools (Table). The expression and function of the newly cloned PDE families (PDE7 to PDE11) in the heart have not been well documented, likely because of the absence of selective inhibitors and lack of antibodies.

Each tissue/cell type expresses a distinct set of PDEs. In cardiac myocytes, multiple PDE isozymes from at least 5 different families have been described. These include PDE1, PDE2, PDE3, PDE4, and PDE5. PDE1, PDE2, and PDE3 show dual substrate specificity in vivo, whereas PDE4 and PDE5 selectively hydrolyze cAMP and cGMP, respectively. The existence of multiple PDE isoforms expressed in a single cell guarantees heterogeneous spatiotemporal patterns of cyclic nucleotide signaling and versatile cyclic nucleotide-mediated functions.

Alterations in PDE expression and activity may disturb the balance and/or localization of cyclic nucleotides and lead to pathological events. In a study of frog myocytes, for instance, PDE inhibition caused a reduction of cAMP effects on Ca2+i channels because of disruption of proper subcellular cAMP localization. Also, in rat neonatal cardiac myocytes, on β-AR stimulation, cAMP elevation and protein kinase A (PKA) activation occur in specific compartments proximate to the transverse tubule. Inhibition of PDEs have been shown to disturb the cAMP gradients and cause a global activation of PKA, which may reveal nonspecific and toxic effects. Depletion of PDE4 expression, through PDE4D gene knock out, has been shown to cause PKA hyperphosphorylation of RyR2, Ca2+ leakage, and cardiac dysfunction. Moreover, chronic inhibition of PDE4 activity by rolipram has been shown to induce exercise-triggered arrhythmias in these mice. Several clinical trials have also linked chronic administration of PDE3 inhibitors to increased mortality, primarily resulting from arrhythmia and sudden death. Taken together, these findings strongly suggest that downregulation of PDE expression in disease states, or chronic inhibition of PDE activity, may impair physiological responses while promoting pathological responses. This review highlights the role of cAMP-hydrolyzing PDE3 in the cardiac muscle, the potential cellular and molecular mechanisms of adverse cardiac effects of chronic PDE3 inhibition, as well as PDE3 regulation and function in the development of heart failure.
PDE1 and PDE3 may differentially contribute to myocardial cAMP hydrolysis under basal and Ca\(^{2+}\)-stimulated conditions. It has also been reported that PDE1 represents the major cGMP-hydrolyzing activity in the human heart. However, the abovementioned studies did not determine the identity of PDE1 isofrom(s) expressed in human myocardium. In addition to human myocardium, the expression of PDE1A has been described in canine hearts. In rat hearts, PDE1 activity has been shown to represent a major cGMP-hydrolytic activity in the first peak eluting from the anion-exchange column, which is contributed by both PDE1A (50%) and PDE1C (10%), respectively. PDE1C expression level has also been found to be induced in 7-oxo-prostacyclin–preconditioned rat hearts. All of these abovementioned studies support the fact that PDE1 activity exists in whole hearts or ventricular tissues; however, an early study from Bode et al disputes the possibility for the expression of PDE1 in rat cardiac myocytes. For example, the report by the authors reveals predominant PDE1 activity in a nonmyocyte soluble fraction of rat ventricular tissue rather than cardiac myocytes, although this study could not rule out the possibility of an existing particulate PDE1 in cardiac myocytes. Immunofluorescent staining has shown that most PDE1A in the rat heart is in the smooth muscle cells of muscular arteries. These data together suggest that PDE1 might be expressed in noncardiac myocytes in the rat heart. Future studies are required to further characterize the individual PDE1 isoforms and cell types in the heart from various species.

Both PDE2 and PDE3 are able to hydrolyze cAMP and cGMP with high affinities. PDE2 family members are often referred to as cGMP-stimulated PDEs because binding of cGMP to the N-terminal GAF domains (cGMP-binding phosphodiesterase, Anabaena adenyl cyclase Escherichia coli FhCAs) of PDE2 greatly stimulates its catalytic activity. In contrast, the \( V_{\text{max}} \) of PDE3 for hydrolyzing cAMP is \( \approx 10 \)-fold greater than that for cGMP. Thus, cGMP behaves as a competitive inhibitor of cAMP hydrolysis because of the high affinity and the low rate of cGMP hydrolysis. For this reason, PDE3 isoforms are also called cGMP-inhibited PDEs. The cGMP-dependent regulation of cAMP-hydrolyzing activities by PDE2 and PDE3 represent important mechanisms by which the cGMP signal regulates cAMP response in several different cell types. For example, atrial natriuretic peptide inhibits adenocorticotroic hormone–induced aldosterone production through cGMP-dependent activation of PDE2 and thereby attenuates adenocorticotropic hormone–stimulated cAMP signaling. In vascular smooth muscle cells (VSMCs), nitric oxide (NO) activates PKA signaling through cGMP-dependent inhibition of PDE3 and elevation of cAMP, which is believed to mediate a variety of NO effects on VSMCs, such as endothelium-dependent smooth muscle relaxation, and inflammatory response. Similarly, NO inhibition of platelet aggregation occurs, at least in part, through inhibiting PDE3 and increasing cAMP. However, in cardiac myocytes, it appears that the roles of PDE2 and PDE3 in cGMP-dependent regulation of cAMP and cardiac functions, in the case of the cardiac L-type \( \text{Ca}^{2+} \) channel current \( I_{\text{ca}} \), vary in different species and the source of myocytes (ventricular versus atrial). Studies of frog ventricular myocytes, rat ventricular myocytes, and human atrial myocytes have demonstrated that cGMP activates cGMP-stimulated PDEs (PDE2), decreases cAMP accumulation, and attenuates cAMP-stimulated \( I_{\text{ca}} \). However, it has also been reported that cGMP inhibits PDE3, increases cAMP, and promotes cAMP-stimulated \( I_{\text{ca}} \) in isolated human atrial myocytes. PDE2 and PDE3 may also differentially regulate \( I_{\text{ca}} \) in response to different concentrations of NO donors in the same frog ventricular myocytes. For instance, PDE3 plays a major role in potentiation of cAMP-stimulated \( I_{\text{ca}} \) when the concentrations of NO donors (such as 3-morpholinosydnonimine and sodium nitroprusside) are in the nanomolar range (low). whereas PDE2 plays a major role in attenuation of cAMP-stimulated \( I_{\text{ca}} \) when the concentrations of NO donors are in the micromolar range (high). These are consistent with the fact that the \( K_{\text{i}} \) value for cGMP inhibition of PDE3 is much lower than the \( K_{\text{i}} \) value for cGMP activation of PDE2. Moreover, cGMP has been shown to activate PKG and inhibit cAMP-stimulated \( I_{\text{ca}} \) independent of PDE in several types of mammalian ventricular myocytes such as rat, rabbit, and human. Therefore, cGMP-dependent regulation of cAMP signaling and myocyte function appears species and myocyte specific, which is probably determined by the relative expression levels of PDE2 versus PDE3, the cGMP concentrations, and/or the compartmentation of PDEs and cGMP.

PDE4 belongs to a large family of enzymes that specifically hydrolyze cAMP with high affinity. Four PDE4 genes (PDE4A, PDE4B, PDE4C, and PDE4D) have been identified, and each of them results in multiple variants through alternative promoters and/or splicing. PDE4 isoforms are found in almost all cell types, and each cell often expresses more than 1 PDE4 isoform. The expression and function of PDE4s in hearts have not been studied extensively because PDE4 inhibitors result in minimal inotropic effects in humans. However, it has recently been reported that depletion of PDE4D gene in mice results in a progressive cardiomyopathy in senescent mice and accelerated heart failure after myocardial infarction. The cardiac deleterious effect of PDE4D knockout is believed to be attributable to loss of PDE4D3 from the macromolecular complex of ryanodine receptor (RyR2), a cardiac calcium channel present in the sarcoplasmic reticulum membrane. Loss of PDE4D3 in the RyR2 complex causes PKA hyperphosphorylation of RyR2, \( \text{Ca}^{2+} \) leakage, and, in turn, cardiac dysfunction. Furthermore, PDE4D3 has been found in human RyR2 macrocomplex and to be decreased in human failing hearts, where the RyR2 is PKA hyperphosphorylated. In addition, in rat neonatal cardiac myocytes, PDE4D3 and PDE4D5 are found to be recruited to membrane \( \beta_{2}-\text{AR} \) via \( \beta_{2}-\text{AR} \) protein switching from G(s) to G(i). Moreover, a cAMP-responsive macromolecular complex has been found in the myocyte nuclear envelope, which contains the muscle-specific A kinase anchoring protein (mAKAP), PKA, PDE4D3, big mitogen-activated kinase 1/extracellular signal-regulated kinase 5 (BMK1/ERK5), the small GTPase Rap1, and the exchange factor Epac. PDE4D3 functions as an adaptor protein that recruits Epac.
activates the small GTPase Rap1, and attenuates ERK5 activation, which plays a critical role in the regulation of myocyte hypertrophy. PDE4, together with PDE3, provides the major cAMP-PDE activity in the heart. However, the relative contributions might be species specific. In rat neonatal cardiac myocytes, PDE4, but not PDE3, appears to be responsible for modulating the amplitude and duration of the cAMP response to β agonists. This is consistent with the observations that PDE4 inhibitors enhance only β-AR agonist–induced cAMP accumulation and contractility in rats.

**PDE3 Isozymes**

The PDE3 gene family contains 2 subfamilies, PDE3A and PDE3B, that are encoded by 2 different but highly related genes. At least 3 PDE3A-related proteins with different apparent molecular masses have been described. They are 136, 118, and 94 kDa and referred to as PDE3A1, PDE3A2, and PDE3A3, respectively. Different PDE3A proteins may be generated by excluding different amounts of 5′-coding sequences via alternative splicing, transcription promoters, or translation start sites. Although all of these PDE3A proteins may have an identical C-terminal portion that contains the PDE catalytic domain, they differ considerably in the N-terminal portion (Figure 1). The N-terminal hydrophobic domains, NHR1 (∼200 aa, with 6 predicted transmembrane helices) and NHR2 (∼50 aa), are believed to be involved in targeting PDE3A subcellular localization, which are differentially distributed in distinct PDE3A proteins. For example, PDE3A1, containing both NHR1 and NHR2, is usually found in the particulate fraction. PDE3A2 (containing an intact NHR2) is found in both cytosolic and particulate fractions, and PDE3A3 (lacking both NHR1 and NHR2) is predominantly cytoplasmic.

The 3 PDE3A isoforms may be translated from 2 mRNA transcripts: PDE3A1 (136 kDa) is derived from PDE3A1 mRNA, whereas PDE3A2 (118 kDa) and PDE3A3 (94 kDa) are the products of PDE3A2 mRNA, probably translated from different AUGs (start codons) in PDE3A2 mRNA. This implies that PDE3A may be regulated at both the transcriptional and posttranscriptional level, resulting in several isoforms with distinct subcellular localization and functional properties. So far, only 1 PDE3B isoform, 137-kDa PDE3B1, has been described. Despite having a divergent N-terminal region, PDE3B1 shares a nearly identical structure with PDE3A1, and it is also membrane associated. A more detailed description of the structural topology of PDE3 isoforms is described in a review by Shakur et al.

PDE3A is relatively abundant in cardiac myocytes, VSMCs, and platelets, whereas PDE3B is predominantly expressed in adipocytes, hepatocytes, and pancreatic cells. In the mammalian heart, 3 PDE3A protein products with molecular masses of 136, 118, and 94 kDa have been detected using PDE3A antibodies. However, it has still not been determined whether proteolysis of PDE3 accounts for the lower-molecular-mass products reported. Using human myocardium fractions, studies have found PDE3A1 (136 kDa) mostly in the microsomal (sarcoplasmic reticulum) fraction, PDE3A2 (118 kDa) in both the microsomal and cytosolic fractions, and PDE3A3 (94 kDa) absolutely in the cytosolic fraction of human myocardium. Two mRNA molecules, probably corresponding to PDE3A1 and PDE3A2/PDE3A3, have been detected by Northern blotting and RNase protection analyses. These observations are consistent with several early studies showing PDE3 activity present in both cardiac microsomal and cytosolic fractions in several different species. The functional properties of these PDE3A enzymes with distinct subcellular localizations are still not well characterized.

The existence of PDE3B1 in heart tissue has only recently been reported in mice. Patrucco et al demonstrate that PDE3B activity accounts for 30% of the total PDE3 activity in the mouse heart and that cardiac PDE3B constitutively associates with phosphoinositide 3-kinase γ (PI3Kγ). PI3Kγ controls L-type calcium current through its positive modulation of PDE3B. Because myocardial tissues contain multiple cell types (such as cardiac myocyte, cardiac fibroblast, or cells from the vasculature), the source of each PDE3 isoyme detected in the heart is still not clear. It is possible that multiple PDE3 isoymes with distinct subcellular localizations coexist in a single cell type. For example, cytosolic PDE3A2 and PDE3A3 and membrane PDE3B1 have been detected in VSMCs. Taken together, these findings suggest that multiple PDE3 isoforms may be expressed in distinct cellular sites and may regulate different biological processes in the heart.

**PDE3 and Heart Failure**

**PDE3 Inhibitors in Heart Failure: Therapeutic Effects and Mechanism of Action**

PDE3-selective inhibitors such as amrinone, enoximone, and milrinone have been used clinically to acutely treat congestive heart failure. In human myocardium, PDE3 inhibi-
tors increase the rate and magnitude of developed force as well as enhance the rate of muscle relaxation. Concurrently, in human vasculature, PDE3 inhibition reduces total peripheral and pulmonary vascular resistance and enhances coronary blood flow. Thus PDE3 inhibitors are powerful drugs for the acute treatment of the congestive heart failure because of simultaneous increased contractility of the heart and decreased resistance of blood flow through the vasculature. Such combined inotropic and vasodilatory actions make PDE3 inhibitors a more effective therapy than either inotropic or vasodilator therapy alone in improving cardiac performance in heart failure patients.

The biochemical and molecular mechanisms by which PDE3 inhibitors reduce vascular resistance are well known. Inhibition of PDE3 enzyme(s) in VSMCs leads to cAMP elevation and PKA activation, which stimulates smooth muscle cell relaxation via PKA-dependent decrease of intracellular Ca\(^{2+}\) concentration and attenuation of myosin phosphorylation.\(^{61,62}\) The cardiotonic effects of PDE3 inhibitors apparently involve 2 different mechanisms of action. (1) Elevation of cAMP via PDE3 inhibition activates PKA, which results in increase in the trans-sarcolemmal influx of Ca\(^{2+}\), probably via phosphorylation and activation of L-type Ca\(^{2+}\) channel, and, in turn, triggers a much larger Ca\(^{2+}\) mobilization from sarcoplasmic reticulum store via RyR2.\(^{42,63-66}\) In the short term, this enhances left ventricular (LV) contractile force and overall systolic function. (2) The cAMP raised by PDE3 inhibition stimulates the Ca\(^{2+}\) uptake through sarcoplasmic reticulum Ca\(^{2+}\)-ATPase (SERCA2 pump), probably via PKA-dependent phosphorylation of phospholamban.\(^{63,67-69}\) This event leads to LV relaxation and improves diastolic function. A strong correlation has been observed between positive inotropic response and membrane-bound PDE3 activity, suggesting the membrane-associated PDE3 may be the site of the inotropic effect of PDE3 inhibitor.\(^{40,52}\) The inotropic connection with PDE3 inhibitors appears to vary across species, and this discrepancy might be attributable to the species-dependent expression of the membrane-associated PDE3 isoform.\(^{40}\) For example, the PDE3 inhibitor imazodan elicited potent inotropic effects on LV muscles from monkeys and dogs, in which a membrane-associated PDE3 activity was identified.\(^{40}\) However little inotropic effect was seen in the rat, hamster, and guinea pig, in which soluble PDE3 activity was much more profound.\(^{40}\)

Conversely, in long-term clinical trials, the early hemodynamic improvements were typically not sustained, and increased mortality attributable to arrhythmias and sudden death has often been reported. Notably, in the PROMISE (Prospective Randomized Milrinone Survival Evaluation) study, oral milrinone (40 mg daily) showed a 28% increase in mortality in patients with class III and IV heart failure. The mortality rate was 53% in patients with class IV heart failure,\(^7\) suggesting that the adverse effect of milrinone is greater in patients with more severe heart failure. Similar observations were obtained from other clinical trials with different PDE3 inhibitors (see reviews for various clinical trials\(^{8,70}\)). Thus, PDE3 inhibitors are reserved for only the acute (rather than chronic) treatment of severe heart failure. Similar effects on increased mortality have been observed with chronic \(\beta\)-AR agonist therapy in heart failure patients.\(^{71-73}\) These results suggest that short-term increase of cAMP through PDE3 inhibition or \(\beta\)-AR stimulation is beneficial to patients with heart failure whose contractility is impaired, but long-term increase of cAMP is harmful.

It is somewhat interesting that another PDE3 inhibitor, cilostazol (a quinolinone derivative), which has a much weaker positive inotropic effect than milrinone, also lacks significant adverse cardiac effects. Cilostazol (Pletal) has been used clinically to treat symptoms of intermittent claudication for decades in Japan and other Asian countries and more recently in the US. The therapeutic effects of cilostazol are mainly attributed to its vasodilatory and antiplatelet actions, via raising intracellular cAMP levels in VSMCs and platelets, respectively. An adjunct to inhibiting PDE3, cilostazol also blocks adenosine uptake, which may distinguish it from other PDE3 inhibitors such as milrinone.\(^{74}\) It has been reported in smooth muscle and platelets that elevated interstitial and circulating adenosine levels by cilostazol could potentiate its cAMP-raising effect through inhibiting PDE3 and, thereby, augmenting antiplatelet and vasodilatory effects of the drug\(^{74}\); whereas in the heart, interstitial adenosine elevation by cilostazol attenuates cAMP response through PDE3 inhibition and thus eliminates the cAMP elicited cardiac effects.\(^{74-76}\) Therefore, the inhibitory effect of cilostazol on adenosine uptake may lessen its cardiac effects including the beneficial acute inotropic effects as well as the detrimental chronic effects of cAMP.

**Alteration of PDE3 Expression in Failing Hearts**

Because the hemodynamic effects are not sustained and mortality is increased with chronic PDE3 inhibitor therapy, changes in PDE3 expression have been investigated as a link to progressive heart failure. Several early studies using LV muscles from patients with various stages of heart failure have shown reduced positive inotropic effects of PDE3 inhibitors with the progression of heart failure.\(^{77,78}\) This loss of cardiac efficacy of PDE3 inhibitors has been proposed to associate with disease-related reduction of PDE3 function.\(^{77,78}\) Further investigation indeed revealed a 50% to 70% reduction of PDE3 activity in the LV myocardium from human hearts with idiopathic cardiomyopathy, compared with normal hearts.\(^79\) Moreover, we have recently demonstrated that the overall PDE3 activity and PDE3A protein levels are significantly reduced in LV myocardial samples from end-stage heart failure patients with both dilated cardiomyopathy and ischemic heart disease.\(^80\) However, a report by Movsesian et al demonstrates no significant alteration in PDE3 activity in the microsomal fractions of human failing hearts.\(^81\) The decrease of PDE3 expression/activity has also been observed in several animal models of heart disease. For example, PDE3 activity in LV endocardium has been shown to be decreased in pacing-induced failing canine hearts, which accompanied desensitized inotropic effects of milrinone.\(^82\) A similar pacing-induced canine heart failure model demonstrated a 50% to 59% reduction of PDE3A mRNA levels in both LV and RV of failing canine hearts.\(^83,84\) Consistent with the mRNA changes, PDE3A protein products, corresponding to microsomal 135 kDa, cytosolic 120
kDa, and cytosolic 80 kDa, were all found to be decreased in the canine failing hearts.\textsuperscript{84} Recently, we have further shown a time-dependent downregulation of PDE3A protein expression in a mouse model of heart failure induced by chronic pressure overload via thoracic aorta constriction for up to 8 weeks.\textsuperscript{80} Because excessive neurohormonal activation of the angiotensin and adrenergic systems contribute to progressive ventricular remodeling and worsening cardiac function,\textsuperscript{85,86} the expression of PDE3A was directly evaluated in rodent hearts receiving chronic angiotensin II (Ang II) or \( \beta \)-AR stimulation. We found that PDE3A protein is downregulated in hypertrophied rodent hearts with chronic infusion of Ang II or \( \beta \)-AR agonist isoproterenol (ISO).\textsuperscript{87} However, an enhancement of PDE3B activity and gene expression was reported in rat hypertrophied and failing hearts with salt-induced hypertension.\textsuperscript{88} Taken together, despite a few opposing reports of PDE3 activity/expression in failing hearts,\textsuperscript{81,88} most of the abovementioned evidence indirectly or directly indicates a downregulation of PDE3 expression/activity in failing hearts. The correlation between PDE3 downregulation and heart failure suggests that downregulation of PDE3 may play a causative role in the development of heart failure. PDE3A knockout mice (PDE3A\textsuperscript{\textminus}), however, did not spontaneously develop noticeable cardiac abnormalities during their normal adulthood.\textsuperscript{89} Most likely, depletion of PDE3A alone is insufficient to induce cardiac dysfunction in mice under the normal physiological circumstances, and additional cardiac stresses are necessary. For example, PDE4D\textsuperscript{\textminus} mice did not spontaneously develop heart failure until senescence, when the heart shows many pathological changes.\textsuperscript{6} In young PDE4D\textsuperscript{\textminus} mice, accelerated heart failure was observed only after applying myocardial infarction.\textsuperscript{6} Similarly, PI3K\textsuperscript{\textminus} mice developed heart failure only in the presence of chronic pressure overload.\textsuperscript{54} Therefore, it will be interesting to challenge the PDE3A\textsuperscript{\textminus} mice with pathological stresses such as pressure overload by thoracic aorta constriction or myocardial infarction.

Pathological Roles of PDE3 Downregulation

### PDE3 and Cardiac Myocyte Apoptosis

The progressive loss of cardiac myocytes caused by apoptosis is critical in pathological cardiac remodeling and heart failure.\textsuperscript{90,91} To determine the role of PDE3 downregulation in cardiac myocyte pathology, the effects of PDE3 inhibition on cardiac myocyte apoptosis have been evaluated in vitro.\textsuperscript{80,87} We found that 2 different PDE3 selective inhibitors, milrinone and cilostamide, significantly increased rat neonatal cardiac myocyte apoptosis similar to that induced by chronic Ang II and \( \beta \)-AR agonist ISO treatment.\textsuperscript{80} As for PDE3 inhibitors, selective downregulation of PDE3A expression using PDE3A antisense also induced myocyte apoptosis.\textsuperscript{80} We found that PDE3A protein and mRNA levels were significantly decreased in primary rat neonatal cardiac myocytes on chronic stimulation with Ang II (via Ang II type 1 receptor [AT1R]) or ISO (via \( \beta \)1-AR),\textsuperscript{80,87} consistent with PDE3 downregulation in rodent heart with chronic infusion of Ang II or ISO in vivo. Interestingly, expression of exogenous wild-type PDE3A1, but not catalytically inactive

PDE3A1, prevented Ang II– and ISO-induced myocyte apoptosis,\textsuperscript{80} indicating that PDE3A downregulation is essential for Ang II– and ISO-induced cardiac myocyte apoptosis.

In rat cardiac myocytes, PDE3 and PDE4 account for the major cAMP-PDE activity,\textsuperscript{41,42} and the cAMP elevation by PDE4 inhibition is much more profound than that by PDE3 inhibition.\textsuperscript{81,80} However, we did not see increased myocyte apoptosis by inhibiting PDE4 activity with PDE4 selective inhibitor rolipram,\textsuperscript{80} suggesting that myocyte apoptosis may be regulated by a subset of cAMP molecules that are preferentially coupled to PDE3A, regardless of the intracellular cAMP levels. PDE4D, however, differentially regulates cardiac myocyte function. For example, PDE4D3, associating with the macrocomplex of RyR2, regulates PKA-dependent RyR2 phosphorylation and function. Loss of PDE4D3 from the RyR2 complex causes leakiness of RyR2 because of PKA hyperphosphorylation of RyR2, which may lead to cardiac dysfunction.\textsuperscript{6} PDE3B has been also found in the mouse heart, constitutively associating with PI3K \( \gamma \) in a multimolecular complex.\textsuperscript{54} PDE3B function was significantly decreased in PI3K\textsuperscript{\textminus} knockout mice (PI3K\textsuperscript{\textminus}), which develop massive myocyte necrosis after chronic pressure overload. However, it is not clear whether the myocyte death in PI3K\textsuperscript{\textminus} mice is attributable to PDE3B dysfunction. Taken together, these observations strongly indicate that different cAMP-hydrolyzing PDEs may regulate spatially and functionally distinct cAMP pools in cardiac myocytes.

### PDE3 and Cardiac Myocyte Gene Expression

Chronic reduction of PDE3 activity may lead to changes in cAMP/PKA-dependent gene expression. Transcriptional activation coupled to cAMP/PKA signaling is through nuclear activators including CREB (cAMP response element–binding protein), CREM (cAMP responsive element modulator), and ATF-1 (activating transcription factor 1). For example, it is well known that increased cAMP activates PKA, which can phosphorylate/activate the transcription activator CREB and subsequently modulate cAMP response element (CRE)-mediated gene expression.\textsuperscript{82} ICERs (inducible cAMP early repressors) are members of the CREM family, which are generated through an alternative promoter (P2) located within an intron near the 3’ end of the CREM gene (Figure 2).\textsuperscript{93,94} Four ICER isoforms (named ICER-I, ICER-\( \gamma \), ICER-II, and ICER-II\( \gamma \)) have been described and are often referred to as ICER collectively because the functional difference of distinct ICER isoforms is not noticed. ICERs are transcriptionally induced by CREB via a CRE-binding sequence in the ICER promoter.\textsuperscript{95} ICER proteins contain DNA-binding and leucine zipper domains but lack the N-terminal transactivation domain, which renders them endogenous inhibitors of gene transcription driven by its cognates such as CREB and ATF-1 (Figure 2).\textsuperscript{93,95} For example, Tomita et al were first to show that ICER is induced by various agonists in the adult hearts and cultured neonatal cardiac myocytes.\textsuperscript{96} And induction of ICER in cardiac myocytes attenuates myocyte hypertrophic growth and promotes myocyte apoptosis by suppressing survival protein Bcl-2 expression.\textsuperscript{96} These findings support an important role of ICER as an inhibitor in CRE-mediated hypertrophic and survival signaling.\textsuperscript{97} In addition to
competing with and thereby repressing CREB-mediated gene transcription, ICER may also inhibit functions of other transcription factors. For example, it has been shown that ICER forms a complex with NFAT (nuclear factor at activated T cells) and inhibits NFAT-dependent gene expression in T lymphocytes.

With this knowledge, the effects of PDE3 inhibition on CREB activation, ICER induction, and Bcl-2 expression in cardiac myocytes have been examined. We found that PDE3 inhibitors milrinone and cilostamide or PDE3A downregulation by its antisense stimulated a sustained CREB activation, ICER induction, and Bcl-2 reduction. Ang II and ISO also stimulated CREB activation, ICER induction, and Bcl-2 reduction, which were prevented by expressing wild-type PDE3A, consistent with observations in myocyte apoptosis. The role of CREB activation and ICER induction in Ang II, ISO, or PDE3 reduction-mediated myocyte apoptosis was further confirmed by the observations that myocyte apoptosis is prevented by blocking CREB activation and ICER expression through overexpression dominant negative CREB or ICER antisense, respectively. Taken together, these results indicate that CREB activation, ICER induction, and Bcl-2 reduction may represent an important mechanism for PDE3 reduction–mediated myocyte apoptosis. Conversely, altering PDE4 activity through PDE4-selective inhibitor or overexpressing PDE4D3 had no significant effects on CREB activation, ICER induction, Bcl-2 expression, which was consistent with observations from cardiac myocyte apoptosis. These findings again suggest that PDE3 and PDE4 may regulate different cAMP/PKA signaling pathways, which have distinct effects on CREB activation, ICER induction, Bcl-2 expression, and myocyte apoptosis. Besides Bcl-2, induction of ICER may change the expression of other genes that are implicated in heart failure. For example, via a microarray analysis, we have seen that sustained expression of exogenous ICER can cause dysregulation of a number of genes that have been reported in failing hearts and that are involved in different aspects of cardiac pathologies. These include structural proteins, ion channels/transporters, signaling molecules, and transcription factors/regulators (Yan C, Abe J, Ding B, Liu W, unpublished data). We further confirmed that the expression of SERCA2 was downregulated by Ang II, ISO, and PDE3 inhibitors and that the ISO-induced downregulation of SERCA2 was prevented by expressing exogenous PDE3A or antisense ICER (Yan C, Abe J, Ding, B, Liu W, unpublished data). SERCA2 plays a critical role in calcium cycling and the beat-to-beat function of the heart. SERCA2 is decreased in animal and human failing hearts, which is associated with impaired cardiac function.

The PDE3-ICER Positive-Feedback Loop and Sustained ICER Expression

Temporally restricted gene expression is critical for many biological processes. Under physiological conditions, ICER expression is a transient phenomenon because ICER is able to block its own transcription by competing with CREB in binding CRE sequences in the ICER promoter. ICER protein levels are decreased by proteasome-dependent degradation. This transient expression of ICER is physiologically important for negative-feedback regulation of CREB-dependent gene expression and allows the gene expression to be activated in a cyclic fashion (Figure 3). For example, CREB-regulated genes are rapidly induced by binding of phosphorylated CREB (p-CREB, activated) to CRE in the promoter regions and then activating transcription, which also includes ICER. Induction of ICER, in turn, leads to termination of mRNA accumulation of CREB-dependent genes as well as ICER itself. The clearance of ICER allows CREB-dependent gene expression to be activated repeatedly. The p-CREB/ICER balanced regulation of gene expression was first described to be essential for circadian rhythm in pineal gland and lately has also been shown to play critical roles in many other types of neuronal cells and nonneuronal systems. In contrast, sustained elevation of ICER levels may cause persistent suppression of CREB-regulated gene expression and thus lead to pathological consequences (Figure 3). For example, it has been shown that expressing exogenous ICER induced cell death in neurons and cardiac myocytes. We have further shown that chronic stimulation with Ang II and β-AR agonist ISO caused sustained ICER induction through PKA-dependent stabilization of ICER protein, which is essential for Ang II– and ISO-induced myocyte apoptosis. Our observations that myocyte apoptosis can be prevented by blocking ICER expression using ICER antisense 24 hours after ICER has been induced further support the notion that persistent but not transient ICER induction is critical for promoting cardiac myocyte apoptosis.

We have discovered that the sustained induction of ICER is maintained by a positive-feedback loop (PDE3A-ICER positive-feedback loop) in which PDE3A is a key mediator (Figure 4). The initiation of ICER expression depends on CREB activation, likely via CREB-dependent ICER gene transcription. ICER represses PDE3A gene transcription by interacting with the PDE3A promoter. PDE3A downregulation activates PKA via increased local cAMP. PKA activation leads to ICER protein elevation by stabilization of ICER protein. This constitutes an autoregulatory positive-feedback loop (Figure 4). Ang II, via AT,R, can initiate this PDE3A-ICER positive-feedback loop by the activation of the classical PKC and CREB pathways. It is noteworthy that Ang II stimulation of AT,R, PKC, and CREB is critical only for the initiation, not the continuation, of the feedback loop. This explains why AT,R antagonists (such as losartan) cannot terminate the feedback loop once it is established. β-AR
stimulation by ISO (via β1-AR) initiates the feedback loop through activation of Ca2+/calmodulin kinase II (Van C, Abe J, Ding B, Liu W, unpublished data) and CREB.87 PDE3 inhibitors can also induce this positive-feedback loop.87 We have demonstrated that this positive-feedback regulatory mechanism is essential for sustained ICER induction and subsequent cardiomyocyte apoptosis induced by Ang II, ISO, and PDE3 inhibitors (Figure 4).87 It appears that this feedback mechanism is not limited only to neonatal cardiomyocytes but also occurs in adult cardiomyocytes. For example, we have confirmed that in adult rat cardiac myocytes, Ang II–induced sustained ICER induction, Bcl-2 reduction, and myocyte apoptosis can be attenuated by preventing the PDE3A-ICER feedback loop via targeting 3 key molecular players in the feedback loop (PDE3A, PKA, and ICER), through overexpressing wild-type PDE3A, the endogenous PKA inhibitor (PKI), and antisense ICER (Figure 5).87 More importantly, the reciprocal and concomitant changes of PDE3A and ICER were also observed in adult human and mouse failing hearts, as well as adult rodent hearts with chronic infusion of Ang II or ISO.80,87 These findings strongly suggest that the positive-feedback loop regulated by PDE3A and ICER is pathologically important in adult hearts.

The fact that expressing exogenous PDE3A blocked the PDE3A-ICER positive-feedback loop and cardiac myocyte apoptosis stimulated by Ang II and β-AR agonist87 suggests that maintaining PDE3A function is critical and that PDE3A gene therapy may represent a strategy to prevent the pathological effects from chronic neurohormonal stimulation. Therefore, it is necessary to further determine whether cardiac-specific expression of exogenous PDE3A is able to protect the heart from cardiac damage and dysfunction induced by various stresses in vivo. In addition, it is also critical to define other regulators and signaling pathways that positively regulate PDE3A expression, which may lead to new therapeutic agents that are capable of maintaining PDE3A function, abrogating the pathogenic PDE3A-ICER positive-feedback loop, and preventing cardiac dysfunction.

The Inhibition of PDE3A-ICER Feedback Loop: Role of Insulin-Like Growth Factor-1–Mediated ERK5 Activation

It has been proposed that the inhibition of cardiomyocyte apoptosis could prevent or slow cardiac failure progression. One of the important cardiomyocyte survival factors is insulin-like growth factor-1 (IGF-1).108–110 Mehrhof et al have reported that IGF-1 activates Akt and ERK1/2 and inhibits apoptosis.111 Although the importance of IGF-1/Pi3-K activation in cell survival is well established,112,113 the specific role of Akt in heart failure has become more complicated by several recently published studies.114–116 For example, Nagoshi et al have reported that ischemia/reperfusion injury is increased in myristoylated Akt Tg (myr-Akt-Tg) mice because of feedback inhibition of insulin receptor substrate-1/Pi3K signaling and suggested an Akt-independent
cardioprotective pathway in IGF-1 signaling may be operative.114 Interestingly, the activity of serum- and glucocorticoid-regulated kinase-1 (SGK-1),117 a downstream substrate of ERK5 that promotes myocyte survival in vitro,118 was downregulated in myr-Akt-Tg mice.114 ERK5/BMK1 is a member of the MAP kinase family. The upstream kinase that phosphorylates ERK5 has been identified as MEK5.119,120 As discussed above, PKA-dependent stabilization of ICER protein is critical for maintaining the PDE3A-ICER feedback loop (Figure 4). ICER stability is regulated by proteasome-dependent degradation.103 cAMP has been shown to attenuate ICER protein ubiquitination and degradation probably via a cAMP-dependent inhibition of MAP kinase ERK1/2.126 It has been shown that ERK1/2 physically interacts with ICER and mediates the phosphorylation of ICER on a critical serine residue (Ser-41) in mouse pituitary tumor AtT20 cells that promotes ICER degradation.126 In this report, the involvement of MEK1/2 and ERK1/2 was proposed because inhibitor PD98059 (initially defined as a MEK1/2 inhibitor)
inhibited epidermal growth factor–induced ICER phosphorylation and degradation. However, recent studies indicate that PD98059 also effectively inhibits MEK5 and ERK5 pathway. Therefore, epidermal growth factor–induced phosphorylation of ICER is possible, in part or entirely, through the MEK5/ERK5 pathway. In fact, we found that activation of ERK5 significantly decreased forskolin-enhanced ICER stability (Yan C, Abe J, Ding B, unpublished data, 2006).

Taken together, our results suggest 2 potential mechanisms by which ERK5 activation intervenes PDE3A-ICER feedback loop: (1) blocking PDE3A downregulation via MEK2-mediated regulation of PDE3A promoter activity and (2) promoting ICER degradation via ERK5 phosphorylation of ICER. Further investigation will be required to define the precise mechanisms of ERK5 activation in antagonizing PDE3A-ICER feedback loop.

Conclusion

Multiple distinct PDE isoforms coexisting in cardiac myocytes concertedly and differentially regulate the temporal, spatial, and kinetic properties of cyclic nucleotide responses. Precise time, duration, and location of cyclic nucleotide elevation are critical for specifically regulating signaling pathways that result in physiological consequences. Long-term alteration of PDE activity/expression, which is vital for normal physiological function, may bring about undesired toxic effects and pathological consequences. Using PDE3 as an example, PDE3A expression is significantly downregulated in failing hearts because of a variety of etiologies. Chronic inhibition of PDE3 activity by PDE3 inhibitors in vitro induces sustained expression of transcription repressor ICER and thereby cardiac myocyte apoptosis and SERCA2 downregulation. These findings suggest that PDE3A reduction observed in failing hearts may play a causative role in the development of heart failure. Sustained ICER induction is permitted by an autoregulatory positive-feedback loop (PDE3A-ICER positive-feedback loop) in which PDE3A and ICER are key mediators. Pathological stresses (such as chronic pressure overload) and neurohormonal overactivation promote, whereas cardiac protective signaling IGF1/ERK5 attenuates, the PDE3A-ICER feedback loop (Figure 6). Sustained ICER expression resulting from the feedback loop is not only essential for cardiac myocyte apoptosis but may also contribute to other protein alteration and cardiac malfunction associated with heart failure (such as contractile dysfunction attributable to SERCA2) (Figure 6). Maintaining PDE3A function may abrogate the pathogenic PDE3A-ICER positive-feedback loop and prevent cardiac myocyte apoptosis and cardiac dysfunction.

References


Sources of Funding

This work was supported by American Heart Association Grant 0455847T (to C.Y.) and NIH grants HL077789 (to C.Y.), HL-66919 (to J.A.), HL-077789 (to J.A.), and GM-071485 (to J.A.).

Disclosures

None.

Figure 6. Proposed model showing the regulation and function the PDE3A-ICER feedback loop. Pathological stimuli (such as chronic pressure overload and neurohormonal overactivation) promote the PDE3A-ICER feedback loop via initial activation of CREB, whereas cardiac protectors (such as IGF-1) attenuate it through activation of ERK5. The persistent ICER induction resulting from the PDE3A-ICER feedback loop dysregulates the expression of a number of proteins (such as downregulation of Bcl-2 and SERCA2) and may, in turn, lead to cardiac myocyte death and contractile dysfunction, which is associated with impaired cardiac function.


42. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res. 1987; 60:539–547.


44. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res. 1987; 60:539–547.
89. Stehle JH, Foulkes NS, Molina CA, Simonneaux V, Pevet P, Sassone-Corsi P. Adrenergic signals direct rhythmic expression of tran-


Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart
Chen Yan, Clint L. Miller and Jun-ichi Abe

Circ Res. 2007;100:489-501
doi: 10.1161/01.RES.0000258451.44949.d7
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/100/4/489

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/